Instrumento Inactivo

Otros idiomas First Light Acquisition Group, Inc. Nyse

Acciones

FLAG.U

US3207032000

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Join Calidi Biotherapeutics Exclusive Live Investor Webinar and Q&A Session on April 24	24/04
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24	23/04
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering	19/04
Calidi Biotherapeutics Prices $6.1 Million Offering	16/04
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering	16/04
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024	10/04
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024	09/04
Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding	21/03
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results	15/03
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer	11/03
Calidi Biotherapeutics, Inc. announced that it expects to receive $3.5 million in funding	08/03
Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference	12/02
Sector Update: Health Care Stocks Firmer Late Afternoon	07/02
Calidi Biotherapeutics to Sell Common Stock	07/02
Calidi Biotherapeutics, Inc. announced that it has received $1 million in funding	26/01
Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board	08/01
Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments	08/01
Calidi Biotherapeutics, Inc.(NYSEAM:CLDI) added to S&P TMI Index	18/12
Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPre to its Board of Directors	13/12
Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit	13/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas First Light Acquisition Group, Inc. Nyse

Acciones

FLAG.U

US3207032000

Otros idiomas

Filtros